The reported anti-tumor effect of Rac1 and Pak1 inhibitors in lung cancer models and the evidence for enhanced Pak1 activation in lung cancer (Gastonguay et al., 2012; Mortazavi et al., 2015; Wu et al., 2016) are strong indicators of Rac1 hyperactivation. Here, RAC1 is linked to lung cancer.